Company Description
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer.
The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients.
The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020.
CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jan 25, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 113 |
| CEO | Arthur Kuan |
Contact Details
Address: 400 Spectrum Center Drive, Suite 2040 Irvine, California 92618 United States | |
| Phone | 949 409 3700 |
| Website | cgoncology.com |
Stock Details
| Ticker Symbol | CGON |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001991792 |
| CUSIP Number | 156944100 |
| ISIN Number | US1569441009 |
| Employer ID | 37-1611499 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Arthur Kuan | Chairman and Chief Executive Officer |
| Ambaw Bellete M.S. | President and Chief Operating Officer |
| Corleen M. Roche | Chief Financial Officer |
| Robert Lapetina | Interim Principal Financial and Accounting Officer |
| Swapnil Bhargava Ph.D. | Chief Technical Officer |
| Amy Steele | Vice President of Finance and Administration |
| Joshua F. Patterson | General Counsel, Chief Compliance Officer and Secretary |
| Sarah Connors | Vice President of Communications and Patient Advocacy |
| Bing Kung | Vice President of Corporate Development |
| Dr. Vijay Kasturi M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 17, 2025 | 144 | Filing |
| Jul 11, 2025 | 8-K | Current Report |
| Jun 6, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| Apr 28, 2025 | 8-K | Current Report |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |